

## Examining the Evidence for Improving Outcomes in Venous Occlusive Disease: Pharmacist Perspectives (Podcast)

### References:

Copeland EA. Hematopoietic stem-cell transplantation. *N Engl J Med* 2006;354:1813-26.

Fan CQ, Crawford JM. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). *J Clin Exp Hepatol* 2014;4:332-46.

Mahadeo KM, Bahwa R, Abdel-Azim H, et al. Diagnosis, grading, and treatment recommendations for children, adolescents and young adults with sinusoidal obstructive syndrome: an international expert position statement. *Lancet Haematol* 2019 [https://doi.org/10.1016/A2352-3026\(19\)30201-7](https://doi.org/10.1016/A2352-3026(19)30201-7). Published on-line December 6, 2019.

Richardson PG, Triplett BM, Ho VT, et al. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. *Exp Rev Clin Pharmacol* 2018;11:113-124.

Corbacioglu S, Cesaro C, Faraci M, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomized controlled trial. *Lancet* 2012;379:1301-9.

Richardson PG, Riches ML, Kernan NA, et al. Phase III trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. *Blood* 2016;127:1656-65.

Kernan NA, Grupp S, Smith AR, et al. Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome. *Br J Haematol* 2018;181:816-27.